GlassScriptPhysician profile
Michael J Alazard
NPI 1851359491
$936.64
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $113 · 2021: $538 · 2022: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $345.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $170.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $168.06 | 2019-2022 | |
| Kaleo, INC. | $47.67 | 2021-2022 | |
| Pfizer INC. | $43.84 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $38.56 | 2021 | |
| Shire North American Group INC | $33.85 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.23 | 2019 | |
| Boston Scientific Corporation | $24.05 | 2019-2020 | |
| Sanofi Pasteur INC. | $19.24 | 2022 | |
| Cranial Technologies, INC | $11.93 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alazard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.